Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUGUST-AHF cohort study of Yiqi Fumai Lyophilized Injection in acute heart failure
ChiCTR2200065913Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of yiqi fumai in Acute Heart Failure (AHF), sponsored by Beijing University of Chinese Medicine. Primary endpoint: 90-day all-cause mortality or readmission for heart failure. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
yiqi fumai
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ChiCTR2200065913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065913.